Read More

The Global Antibiotic Research & Development Partnership, In Collaboration With Innoviva Specialty Therapeutics, Subsidiary Of Innoviva Announced Results In Largest Pivotal Phase 3 Trial Of A First-In-Class Oral Antibiotic To Treat Uncomplicated Gonorr…

A Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current international standard of care.Positive top-line study

INVA

Read More

XACDURO, The First And Only Antibiotic Developed To Target Acinetobacter, Now Available To Treat Hospital-Acquired Bacterial Pneumonia And Ventilator-Associated Bacterial Pneumonia In Adults

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems (CRAB).In the U.S.,

INVA